TY - JOUR
T1 - Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma
AU - Oudard, Stephane
AU - Benhamouda, Nadine
AU - Escudier, Bernard
AU - Ravel, Patrice
AU - Tran, Thi
AU - Levionnois, Emeline
AU - Negrier, Sylvie
AU - Barthelemy, Philippe
AU - Berdah, Jean François
AU - Gross-Goupil, Marine
AU - Sternberg, Cora N.
AU - Bono, Petri
AU - Porta, Camillo
AU - De Giorgi, Ugo
AU - Parikh, Omi
AU - Hawkins, Robert
AU - Highley, Martin
AU - Wilke, Jochen
AU - Decker, Thomas
AU - Tanchot, Corinne
AU - Gey, Alain
AU - Terme, Magali
AU - Tartour, Eric
N1 - Funding Information:
Funding: This research was funded by Glaxo Smith Beecham (GSK) (2017) and the Association Foncer contre le Cancer (2020) and SIRIC CARPEM (2020) and Labex Immuno-Oncology (2021).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+ CD14 and Tie2+ CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+ CD14 and Tie2+ CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+ CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+ CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.
AB - The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+ CD14 and Tie2+ CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+ CD14 and Tie2+ CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+ CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+ CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.
KW - Angiogenesis
KW - Biomarker
KW - Myeloid cells
KW - Pro-angiogenic monocytes
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85121450981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121450981&partnerID=8YFLogxK
U2 - 10.3390/cells11010017
DO - 10.3390/cells11010017
M3 - Article
AN - SCOPUS:85121450981
VL - 11
JO - Cells
JF - Cells
SN - 2073-4409
IS - 1
M1 - 17
ER -